Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN ORIE HERZBERG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1861873275
CMS profile
1359383
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,751.70

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,452.50 2
Food and Beverage $299.20 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,875.00 2
Daiichi Sankyo Inc. $1,712.50 1
Amgen Inc. $117.71 1
Genentech USA, Inc. $46.49 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN ORIE HERZBERG

NPI 1861873275 · CMS profile ID 1359383

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861873275?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861873275?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861873275?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BENJAMIN ORIE HERZBERG, NPI 1861873275, CMS profile ID 1359383, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861873275?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $4,751.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $1,712.5011/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089433368 CMS
AstraZeneca Pharmaceuticals LP $2,740.0009/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104651457 CMS
Genentech USA, Inc. $46.4906/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132981298 CMS
AstraZeneca Pharmaceuticals LP $135.0006/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104437953 CMS
Amgen Inc. $117.7105/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111598828 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $106.30 2
PY2023 $970.06 4
PY2024 $4,751.70 5
PY2025 $18,408.32 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,023,233.04 218
PY2024 Principal investigator $909,794.38 160
PY2023 Principal investigator $870,048.69 649
PY2022 Principal investigator $8,640.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

649 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Astellas Pharma Inc $3,646.77 12/14/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351645
Principal investigator 1 Astellas Pharma Inc $3,646.77 12/14/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351649
Principal investigator 1 Astellas Pharma Inc $3,646.77 12/14/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351653
Principal investigator 1 Astellas Pharma Inc $1,599.75 11/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351641
Principal investigator 1 Astellas Pharma Inc $3,396.60 10/02/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351611
Principal investigator 1 Astellas Pharma Inc $3,285.90 10/02/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351615
Principal investigator 1 Astellas Pharma Inc $3,646.77 10/02/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351619
Principal investigator 1 Astellas Pharma Inc $3,646.77 10/02/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351623
Principal investigator 1 Astellas Pharma Inc $3,285.90 10/02/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351627
Principal investigator 1 Astellas Pharma Inc $133.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352239
Principal investigator 1 Astellas Pharma Inc $30.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352241
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352243
Principal investigator 1 Astellas Pharma Inc $169.38 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352245
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352247
Principal investigator 1 Astellas Pharma Inc $239.22 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352249
Principal investigator 1 Astellas Pharma Inc $405.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352251
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352253
Principal investigator 1 Astellas Pharma Inc $30.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352255
Principal investigator 1 Astellas Pharma Inc $133.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352257
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352259
Principal investigator 1 Astellas Pharma Inc $290.95 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352261
Principal investigator 1 Astellas Pharma Inc $405.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352263
Principal investigator 1 Astellas Pharma Inc $75.46 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352265
Principal investigator 1 Astellas Pharma Inc $234.95 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352267
Principal investigator 1 Astellas Pharma Inc $73.12 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352269
Principal investigator 1 Astellas Pharma Inc $10.50 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352271
Principal investigator 1 Astellas Pharma Inc $10.50 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352273
Principal investigator 1 Astellas Pharma Inc $10.50 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352275
Principal investigator 1 Astellas Pharma Inc $133.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352277
Principal investigator 1 Astellas Pharma Inc $234.95 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352279
Principal investigator 1 Astellas Pharma Inc $133.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352281
Principal investigator 1 Astellas Pharma Inc $30.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352283
Principal investigator 1 Astellas Pharma Inc $405.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352285
Principal investigator 1 Astellas Pharma Inc $169.38 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352287
Principal investigator 1 Astellas Pharma Inc $30.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352289
Principal investigator 1 Astellas Pharma Inc $10.50 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352291
Principal investigator 1 Astellas Pharma Inc $290.95 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352295
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352297
Principal investigator 1 Astellas Pharma Inc $10.50 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352299
Principal investigator 1 Astellas Pharma Inc $10.50 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352301
Principal investigator 1 Astellas Pharma Inc $3,297.90 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352305
Principal investigator 1 Astellas Pharma Inc $234.95 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352307
Principal investigator 1 Astellas Pharma Inc $73.12 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352309
Principal investigator 1 Astellas Pharma Inc $290.95 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352311
Principal investigator 1 Astellas Pharma Inc $239.22 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352313
Principal investigator 1 Astellas Pharma Inc $30.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352315
Principal investigator 1 Astellas Pharma Inc $75.46 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352317
Principal investigator 1 Astellas Pharma Inc $239.22 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352321
Principal investigator 1 Astellas Pharma Inc $73.12 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352323
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352325
Principal investigator 1 Astellas Pharma Inc $30.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352327
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352329
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352331
Principal investigator 1 Astellas Pharma Inc $169.38 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352333
Principal investigator 1 Astellas Pharma Inc $133.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352335
Principal investigator 1 Astellas Pharma Inc $135.00 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352337
Principal investigator 1 Astellas Pharma Inc $75.46 08/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352339
Principal investigator 1 Astellas Pharma Inc $3,646.77 07/25/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352217
Principal investigator 1 Astellas Pharma Inc $3,396.60 07/25/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352235
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352159
Principal investigator 1 Astellas Pharma Inc $3,646.77 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352163
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352167
Principal investigator 1 Astellas Pharma Inc $3,646.77 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352171
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352175
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352179
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352183
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352187
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352189
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352191
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352193
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352195
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352199
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352201
Principal investigator 1 Astellas Pharma Inc $169.38 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352203
Principal investigator 1 Astellas Pharma Inc $234.95 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352205
Principal investigator 1 Astellas Pharma Inc $75.46 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352207
Principal investigator 1 Astellas Pharma Inc $73.12 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352209
Principal investigator 1 Astellas Pharma Inc $405.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352211
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352213
Principal investigator 1 Astellas Pharma Inc $133.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352215
Principal investigator 1 Astellas Pharma Inc $405.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352219
Principal investigator 1 Astellas Pharma Inc $290.95 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352221
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352223
Principal investigator 1 Astellas Pharma Inc $3,297.90 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352225
Principal investigator 1 Astellas Pharma Inc $133.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352227
Principal investigator 1 Astellas Pharma Inc $239.22 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352229
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352231
Principal investigator 1 Astellas Pharma Inc $135.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352233
Principal investigator 1 Astellas Pharma Inc $405.00 07/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352237
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351871
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351880
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351893
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351897
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351901
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351905
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351909
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351913
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351917
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351921
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351925
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351929
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351935
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351939
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351943
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351947
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351951
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351955
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351959
Principal investigator 1 Astellas Pharma Inc $415.13 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351963
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351967
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351971
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351975
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351979
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351983
Principal investigator 1 Astellas Pharma Inc $2,431.35 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351987
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351995
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352011
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352023
Principal investigator 1 Astellas Pharma Inc $3,396.60 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352027
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352035
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352039
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352043
Principal investigator 1 Astellas Pharma Inc $290.95 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352063
Principal investigator 1 Astellas Pharma Inc $11,288.93 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352091
Principal investigator 1 Astellas Pharma Inc $239.22 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352113
Principal investigator 1 Astellas Pharma Inc $675.00 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352117
Principal investigator 1 Astellas Pharma Inc $3,646.77 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352135
Principal investigator 1 Astellas Pharma Inc $3,285.90 05/26/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352139
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351791
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351795
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351799
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351803
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351807
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351815
Principal investigator 1 Astellas Pharma Inc $31.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351819
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351823
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351827
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351831
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351835
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351839
Principal investigator 1 Astellas Pharma Inc $90.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351843
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351847
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351851
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351855
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351859
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351863
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351867
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351875
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351885
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351889
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352015
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352047
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352059
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352071
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352083
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352087
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352125
Principal investigator 1 Astellas Pharma Inc $30.00 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352129
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352147
Principal investigator 1 Astellas Pharma Inc $10.50 05/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352151
Principal investigator 1 Astellas Pharma Inc $3,646.77 05/05/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351811
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351665
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351673
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351677
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351681
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351685
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351689
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351693
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351697
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351701
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351705
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351709
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351713
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351717
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351721
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351725
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351729
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351733
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351737
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351741
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351745
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351749
Principal investigator 1 Astellas Pharma Inc $338.31 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351753
Principal investigator 1 Astellas Pharma Inc $358.35 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351757
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351761
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351765
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351769
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351773
Principal investigator 1 Astellas Pharma Inc $338.31 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351777
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351781
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351785
Principal investigator 1 Astellas Pharma Inc $358.35 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351991
Principal investigator 1 Astellas Pharma Inc $3,297.90 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351999
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352003
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352007
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352019
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352031
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352051
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352055
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352067
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352075
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352079
Principal investigator 1 Astellas Pharma Inc $405.00 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352101
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352105
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352109
Principal investigator 1 Astellas Pharma Inc $234.95 05/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352121
Principal investigator 1 Astellas Pharma Inc $4,200.27 05/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351657
Principal investigator 1 Astellas Pharma Inc $2,647.35 05/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351661
Principal investigator 1 Astellas Pharma Inc $3,646.77 05/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017351669
Principal investigator 1 Astellas Pharma Inc $3,396.60 05/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352097
Principal investigator 1 Astellas Pharma Inc $1,972.35 05/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352142
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352909
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352911
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352913
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352915
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352917
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352919
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352921
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352923
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352927
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352929
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352931
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352933
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352935
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352937
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352939
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352941
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352945
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352947
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352949
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352951
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352953
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352955
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352957
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352963
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352965
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352969
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352971
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352975
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352979
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352981
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352983
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352985
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352987
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352989
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352993
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352999
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353001
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353003
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353005
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353009
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353015
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353017
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353019
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353021
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353023
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353025
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353027
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353029
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353031
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353033
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353035
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353037
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353039
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353041
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353043
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353045
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353047
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353049
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353053
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353055
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353057
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353061
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353063
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353065
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353071
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353073
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353075
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353077
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353079
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353083
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353085
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353087
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353089
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353091
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353093
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353097
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353099
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353101
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353103
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353105
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353107
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353109
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353111
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353113
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353115
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353117
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353119
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353121
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353123
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353125
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353127
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353131
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353133
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353135
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353137
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353141
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353145
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353147
Principal investigator 1 Astellas Pharma Inc $135.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353149
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353151
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353153
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353155
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353157
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353161
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353163
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353165
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353167
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353173
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353175
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353177
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353179
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353181
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353185
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353187
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353193
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353195
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353197
Principal investigator 1 Astellas Pharma Inc $239.22 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353199
Principal investigator 1 Astellas Pharma Inc $169.38 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353203
Principal investigator 1 Astellas Pharma Inc $290.95 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353205
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353209
Principal investigator 1 Astellas Pharma Inc $75.46 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353211
Principal investigator 1 Astellas Pharma Inc $73.12 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353213
Principal investigator 1 Astellas Pharma Inc $133.00 04/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353219
Principal investigator 1 Astellas Pharma Inc $3,396.60 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352967
Principal investigator 1 Astellas Pharma Inc $1,972.35 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352977
Principal investigator 1 Astellas Pharma Inc $3,396.60 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353011
Principal investigator 1 Astellas Pharma Inc $4,985.97 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353051
Principal investigator 1 Astellas Pharma Inc $5,253.16 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353169
Principal investigator 1 Astellas Pharma Inc $2,431.35 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353189
Principal investigator 1 Astellas Pharma Inc $3,414.57 04/19/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353207
Principal investigator 1 Astellas Pharma Inc $30.00 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352961
Principal investigator 1 Astellas Pharma Inc $3,297.90 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352973
Principal investigator 1 Astellas Pharma Inc $135.00 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352995
Principal investigator 1 Astellas Pharma Inc $3,297.90 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353139
Principal investigator 1 Astellas Pharma Inc $10.50 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353143
Principal investigator 1 Astellas Pharma Inc $10.50 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353159
Principal investigator 1 Astellas Pharma Inc $30.00 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353217
Principal investigator 1 Astellas Pharma Inc $135.00 04/10/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353223
Principal investigator 1 Astellas Pharma Inc $3,396.60 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352943
Principal investigator 1 Astellas Pharma Inc $5,253.16 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352959
Principal investigator 1 Astellas Pharma Inc $2,647.35 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352991
Principal investigator 1 Astellas Pharma Inc $3,396.60 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353013
Principal investigator 1 Astellas Pharma Inc $4,200.27 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353059
Principal investigator 1 Astellas Pharma Inc $3,646.77 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353067
Principal investigator 1 Astellas Pharma Inc $4,985.97 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353069
Principal investigator 1 Astellas Pharma Inc $1,599.75 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353081
Principal investigator 1 Astellas Pharma Inc $415.13 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353095
Principal investigator 1 Astellas Pharma Inc $1,972.35 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353129
Principal investigator 1 Astellas Pharma Inc $2,431.35 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353171
Principal investigator 1 Astellas Pharma Inc $415.13 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353183
Principal investigator 1 Astellas Pharma Inc $3,396.60 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353201
Principal investigator 1 Astellas Pharma Inc $3,646.77 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353215
Principal investigator 1 Astellas Pharma Inc $1,972.35 04/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017353221
Principal investigator 1 Astellas Pharma Inc $421.88 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352443
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352445
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352451
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352453
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352455
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352457
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352459
Principal investigator 1 Astellas Pharma Inc $472.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352461
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352467
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352475
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352479
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352481
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352487
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352491
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352495
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352499
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352503
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352519
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352523
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352527
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352529
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352535
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352543
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352545
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352551
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352557
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352559
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352561
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352563
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352571
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352575
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352581
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352589
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352597
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352603
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352607
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352613
Principal investigator 1 Astellas Pharma Inc $540.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352615
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352619
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352625
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352627
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352639
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352641
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352663
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352667
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352669
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352683
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352685
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352689
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352697
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352705
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352715
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352719
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352721
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352723
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352735
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352737
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352743
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352745
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352747
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352757
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352759
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352763
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352765
Principal investigator 1 Astellas Pharma Inc $421.88 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352771
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352777
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352787
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352793
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352799
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352801
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352805
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352815
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352829
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352835
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352841
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352843
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352851
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352865
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352867
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352873
Principal investigator 1 Astellas Pharma Inc $135.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352885
Principal investigator 1 Astellas Pharma Inc $30.00 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352887
Principal investigator 1 Astellas Pharma Inc $10.50 03/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352903
Principal investigator 1 Astellas Pharma Inc $30.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352447
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352449
Principal investigator 1 Astellas Pharma Inc $290.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352465
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352469
Principal investigator 1 Astellas Pharma Inc $135.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352473
Principal investigator 1 Astellas Pharma Inc $75.46 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352483
Principal investigator 1 Astellas Pharma Inc $421.88 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352493
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352497
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352501
Principal investigator 1 Astellas Pharma Inc $338.31 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352513
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352517
Principal investigator 1 Astellas Pharma Inc $30.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352521
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352537
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352539
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352541
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352547
Principal investigator 1 Astellas Pharma Inc $290.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352549
Principal investigator 1 Astellas Pharma Inc $338.31 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352553
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352565
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352567
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352579
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352583
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352585
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352587
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352595
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352601
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352609
Principal investigator 1 Astellas Pharma Inc $290.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352611
Principal investigator 1 Astellas Pharma Inc $135.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352617
Principal investigator 1 Astellas Pharma Inc $10.50 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352623
Principal investigator 1 Astellas Pharma Inc $133.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352629
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352631
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352633
Principal investigator 1 Astellas Pharma Inc $73.12 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352635
Principal investigator 1 Astellas Pharma Inc $169.38 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352637
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352643
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352645
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352647
Principal investigator 1 Astellas Pharma Inc $675.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352651
Principal investigator 1 Astellas Pharma Inc $358.35 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352653
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352655
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352659
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352671
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352677
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352679
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352681
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352687
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352691
Principal investigator 1 Astellas Pharma Inc $239.22 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352693
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352701
Principal investigator 1 Astellas Pharma Inc $133.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352709
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352711
Principal investigator 1 Astellas Pharma Inc $358.35 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352717
Principal investigator 1 Astellas Pharma Inc $135.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352725
Principal investigator 1 Astellas Pharma Inc $30.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352729
Principal investigator 1 Astellas Pharma Inc $169.38 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352733
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352739
Principal investigator 1 Astellas Pharma Inc $133.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352741
Principal investigator 1 Astellas Pharma Inc $30.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352761
Principal investigator 1 Astellas Pharma Inc $169.38 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352775
Principal investigator 1 Astellas Pharma Inc $73.12 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352779
Principal investigator 1 Astellas Pharma Inc $135.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352781
Principal investigator 1 Astellas Pharma Inc $135.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352783
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352789
Principal investigator 1 Astellas Pharma Inc $358.35 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352795
Principal investigator 1 Astellas Pharma Inc $239.22 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352807
Principal investigator 1 Astellas Pharma Inc $10.50 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352811
Principal investigator 1 Astellas Pharma Inc $338.31 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352817
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352821
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352823
Principal investigator 1 Astellas Pharma Inc $75.46 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352833
Principal investigator 1 Astellas Pharma Inc $10.50 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352839
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352845
Principal investigator 1 Astellas Pharma Inc $75.46 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352847
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352853
Principal investigator 1 Astellas Pharma Inc $73.12 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352857
Principal investigator 1 Astellas Pharma Inc $10.50 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352859
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352861
Principal investigator 1 Astellas Pharma Inc $133.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352863
Principal investigator 1 Astellas Pharma Inc $30.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352877
Principal investigator 1 Astellas Pharma Inc $10.50 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352879
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352881
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352883
Principal investigator 1 Astellas Pharma Inc $239.22 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352893
Principal investigator 1 Astellas Pharma Inc $405.00 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352897
Principal investigator 1 Astellas Pharma Inc $234.95 03/27/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352905
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352471
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352485
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352509
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352525
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352569
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352591
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352649
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352713
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352727
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352751
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352791
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352825
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352827
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352849
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352889
Principal investigator 1 Astellas Pharma Inc $73.12 03/23/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352901
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352477
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352489
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352505
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352507
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352511
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352515
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352531
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352533
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352555
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352573
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352577
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352599
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352605
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352621
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352657
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352661
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352665
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352673
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352695
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352703
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352731
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352753
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352755
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352767
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352785
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352797
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352803
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352809
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352813
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352819
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352855
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352871
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352875
Principal investigator 1 Astellas Pharma Inc $75.46 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352891
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352895
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352899
Principal investigator 1 Astellas Pharma Inc $133.00 03/20/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352907
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/13/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352675
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/13/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352699
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/13/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352769
Principal investigator 1 Astellas Pharma Inc $11,288.93 03/13/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352869
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352593
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352707
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352749
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352831
Principal investigator 1 Astellas Pharma Inc $3,297.90 03/01/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352837
Principal investigator 1 Astellas Pharma Inc $4,200.27 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352351
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352353
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352355
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352357
Principal investigator 1 Astellas Pharma Inc $2,431.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352359
Principal investigator 1 Astellas Pharma Inc $5,253.16 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352361
Principal investigator 1 Astellas Pharma Inc $3,414.57 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352363
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352365
Principal investigator 1 Astellas Pharma Inc $4,985.97 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352367
Principal investigator 1 Astellas Pharma Inc $4,985.97 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352369
Principal investigator 1 Astellas Pharma Inc $4,985.97 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352371
Principal investigator 1 Astellas Pharma Inc $1,599.75 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352373
Principal investigator 1 Astellas Pharma Inc $4,985.97 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352375
Principal investigator 1 Astellas Pharma Inc $1,599.75 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352377
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352379
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352381
Principal investigator 1 Astellas Pharma Inc $3,414.57 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352383
Principal investigator 1 Astellas Pharma Inc $3,646.77 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352385
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352389
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352391
Principal investigator 1 Astellas Pharma Inc $1,599.75 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352393
Principal investigator 1 Astellas Pharma Inc $2,647.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352395
Principal investigator 1 Astellas Pharma Inc $2,647.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352397
Principal investigator 1 Astellas Pharma Inc $2,431.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352399
Principal investigator 1 Astellas Pharma Inc $2,431.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352401
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352403
Principal investigator 1 Astellas Pharma Inc $2,647.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352405
Principal investigator 1 Astellas Pharma Inc $4,200.27 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352407
Principal investigator 1 Astellas Pharma Inc $3,285.90 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352409
Principal investigator 1 Astellas Pharma Inc $3,646.77 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352411
Principal investigator 1 Astellas Pharma Inc $5,253.16 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352413
Principal investigator 1 Astellas Pharma Inc $3,646.77 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352415
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352417
Principal investigator 1 Astellas Pharma Inc $1,972.35 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352419
Principal investigator 1 Astellas Pharma Inc $4,200.27 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352421
Principal investigator 1 Astellas Pharma Inc $3,646.77 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352423
Principal investigator 1 Astellas Pharma Inc $3,646.77 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352425
Principal investigator 1 Astellas Pharma Inc $5,253.16 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352427
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352431
Principal investigator 1 Astellas Pharma Inc $3,414.57 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352433
Principal investigator 1 Astellas Pharma Inc $5,253.16 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352435
Principal investigator 1 Astellas Pharma Inc $4,200.27 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352437
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352439
Principal investigator 1 Astellas Pharma Inc $3,396.60 02/24/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352441
Principal investigator 1 Astellas Pharma Inc $1,113.75 01/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352341
Principal investigator 1 Astellas Pharma Inc $6,750.00 01/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352343
Principal investigator 1 Astellas Pharma Inc $4,725.00 01/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352345
Principal investigator 1 Astellas Pharma Inc $270.00 01/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352347
Principal investigator 1 Astellas Pharma Inc $23,490.00 01/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352349
Principal investigator 1 Astellas Pharma Inc $3,000.00 01/30/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1017352429
Principal investigator 1 Amgen Inc. $39,744.00 01/26/2023 Non-covered Recipient Entity
MILSTEIN HOSPITAL
AMG 510 Ph1b Master Protocol 20190135 No dispute reported 06/30/2026 1029648603
Principal investigator 1 Amgen Inc. $39,744.00 01/17/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NY, THE
AMG 510 Ph1b Master Protocol 20190135 No dispute reported 06/30/2026 1029648743
Principal investigator 1 Amgen Inc. $263,592.00 01/03/2023 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NY, THE
AMG 510 Ph1b Master Protocol 20190135 No dispute reported 06/30/2026 1029648749